Compare MicroSectors FANG and Innovation 3X Leveraged ETN (FNGU) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MicroSectors FANG and Innovation 3X Leveraged ETN vs Tango Therapeutics Inc. — how do they compare? MicroSectors FANG and Innovation 3X Leveraged ETN trades at $33.19 (market cap $2.94B), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: Tango Therapeutics Inc. is the larger of the two by market cap, and MicroSectors FANG and Innovation 3X Leveraged ETN is trading nearer its 52-week high, Tango Therapeutics Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold MicroSectors FANG and Innovation 3X Leveraged ETN for 20 Days and Tango Therapeutics Inc. for 0 Days on average.
| FNGU | TNGX | |
|---|---|---|
Market Cap | $2.94B | $3.75B |
Volume | 1,823,720 | 9,619,106 |
Sector | Leveraged / Inverse | Health |
52-Week High | $37.20 | $32.90 |
52-Week Low | $13.73 | $7.50 |
Typical Hold Time | 20 Days | 0 Days |
Enterprise Value | — | $2.77B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FNGU, a 3X leveraged ETN tracking major tech stocks, trades at $36.69 with a slight 0.22% daily gain. Technical indicators show a bullish trend with strong moving average support, though RSI levels suggest potential overbought conditions. The ETN provides triple exposure to tech giants like Nvidia and Apple but carries significant volatility risks as highlighted by recent analysis of its 87% decline during previous market downturns.
The outlook remains tied to the performance of underlying tech stocks, offering amplified gains in bullish markets but severe losses during corrections. Key risks include leverage decay, concentration in mega-cap tech, and market volatility. Investors should weigh the potential for high returns against the substantial downside exposure inherent in leveraged products.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About MicroSectors FANG and Innovation 3X Leveraged ETN
FNGU is a leveraged ETN that seeks to provide three times (3x) the daily performance of top tech and innovation stocks. It is intended for traders seeking magnified short-term returns.
Read more on FNGU →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
